Novartis Loses in Appeal Over Gilenya Patent
22 Junho 2022 - 4:05AM
Dow Jones News
By Maitane Sardon
Novartis AG said late yesterday that a U.S. appeals court has
changed course over a litigation regarding the exclusivity of its
multiple sclerosis blockbuster drug Gilenya and that it plans to
challenge the decision.
The Swiss pharmaceutical company said a modified panel of three
judges of the U.S. Court of Appeals for the Federal Circuit had
found its patent on Gilenya invalid, reversing the court's earlier
ruling.
In August 2020, a U.S. federal court in Delaware blocked Chinese
drugmaker HEC Pharma Co. from launching a generic version of the
drug until the expiration of the Gilenya patent in December 2027.
In January 2022, a three-judge panel of the Federal Circuit upheld
the Delaware's court ruling but HEC Pharma filed a petition for
rehearing.
A split panel on Tuesday reversed the decision, the company
said.
HEC Pharma was the only remaining company challenging the patent
as Novartis had settled with other drugmakers prior to the patent
expiration, the Swiss company added.
"Novartis intends to vigorously defend the validity of the
patent and is considering all available options, including current
plans to seek review of this decision by the full CAFC, a process
which may take several months," the company said.
Write to Maitane Sardon at maitane.sardon@wsj.com
(END) Dow Jones Newswires
June 22, 2022 02:50 ET (06:50 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024